DK1870109T3 - Kombineret vaccine mod mycoplasma hyopneumoniae og porcin circovirus - Google Patents

Kombineret vaccine mod mycoplasma hyopneumoniae og porcin circovirus Download PDF

Info

Publication number
DK1870109T3
DK1870109T3 DK07019279.4T DK07019279T DK1870109T3 DK 1870109 T3 DK1870109 T3 DK 1870109T3 DK 07019279 T DK07019279 T DK 07019279T DK 1870109 T3 DK1870109 T3 DK 1870109T3
Authority
DK
Denmark
Prior art keywords
vaccine composition
pigs
vaccine
mycoplasma hyopneumoniae
challenge
Prior art date
Application number
DK07019279.4T
Other languages
English (en)
Inventor
Wumin Li
Zhichang Xu
Hsien-Jue Chu
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32680190&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1870109(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Application granted granted Critical
Publication of DK1870109T3 publication Critical patent/DK1870109T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Claims (19)

1. Vaccinesammensætning til immunisering af et dyr mod infektion med Mycoplasma hyopneumoniae og porcin circovirus (PCV), som omfatter en immuniserende mængde af Mycoplasma hyopneumoniae-bakterin; en immuniserende mængde af porcin circovirus (PCV); en adjuvansblanding omfattende en acrylsyrepolymer og en blanding af en metaboliserbar olie og en polyoxyethylen-polyoxypropylen-blokcopolymer; og et farmaceutisk acceptabelt bærestof, hvilken vaccinesammensætning fremkalder beskyttende immunitet mod Mycoplasma hyopneumoniae efter en enkelt indgivelse.
2. Vaccinesammensætning ifølge krav 1, hvor adjuvansblandingen består af en acrylsyrepolymer og en blanding af en metaboliserbar olie, der omfatter en eller flere terpencarbonhydrider og en polyoxyethylen-polyoxypropylen-blokcopolymer i et forhold på ca. 1:25 til 1:50 acrylsyrepolymer til metaboliserbar olie/polyoxyethylen-polyoxypropylen-blokcopolymer-blanding.
3. Vaccinesammensætning ifølge krav 1, hvor adjuvansblandingen omfatter ca. 1-25% v/v af vaccinesammensætningen.
4. Vaccinesammensætning ifølge krav 3, hvor acrylsyrepolymeren er til stede i en endelig koncentration på ca. 1 % v/v og terpencarbonhydri-der/polyoxyethylen-polyoxypropylen-blokcopolymer-blandingen er til stede i en endelig koncentration på ca. 5 % til 10 % v/v.
5. Vaccinesammensætning ifølge krav 3, hvor adjuvansblandingen omfatter ca. 2 % -15 % v/v af vaccinesammensætningen.
6. Vaccinesammensætning ifølge krav 5, hvor adjuvansblandingen omfatter ca. 5 % -12 % v/v af vaccinesammensætningen.
7. Vaccinesammensætning ifølge krav 1, hvor den metaboliserbare olie er squalan eller squalen.
8. Vaccinesammensætning ifølge krav 6 eller krav 7, hvor acrylsyrepolyme-ren er en carbomer.
9. Vaccinesammensætning ifølge et hvilket som helst af kravene 1-8, yderligere omfattende mindst et bakterin eller oprenset toksoid udvalgt fra gruppen bestående af Haemonphilus parasuis, Pasteurella multiocida, Streptococcum suis, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Salmonella choleraesuis, Erysipelothrix rhusiopathiae og leptospira-bakterier.
10. Vaccinesammensætning ifølge et hvilket som helst af kravene 1-8, yderligere omfattende et bakterie- eller virusantigen udvalgt blandt et eller flere af følgende: Haemonphilus parasuis, PRRSV, Erysipelothrix rhusiopathiae, Pasteurella multiocida og Bordetella bronchiseptica.
11. Vaccinesammensætning omfattende en immuniserende mængde af et Mycoplasma hyopneumoniae-bakterin; en immuniserende mængde af porcin circovirus (PCV); en adjuvansblanding omfattende en acrylsyrepolymer og en blanding af metaboliserbar olie og en polyoxyethylen-polyoxypropylen-blokcopolymer; og et farmaceutisk acceptabelt bærestof, til anvendelse til beskyttelse af et dyr mod sygdom forårsaget af Mycoplasma hyopneumoniae og porcin circovirus (PCV), hvor vaccinesammensætningen, fremkalder beskyttende immunitet mod Mycoplasma hyopneumoniae-infektion efter en enkelt indgivelse.
12. Vaccinesammensætning til anvendelse ifølge krav 11, hvor den immuniserende mængde af bakterierne er ca. 1 x 108 til 3 x 1011 MHDCE/ml.
13. Vaccinesammensætning til anvendelse ifølge krav 12, hvor den immuniserende mængde af bakterierne er ca. 1 x 109 til 3 x 109 MHDCE/ml.
14. Vaccinesammensætning til anvendelse ifølge krav 11, hvor indgivelsesmåden i indgivelsestrinnet er intramuskulær, subkutan, intraperitoneal, aerosol, oral eller intranasal.
15. Vaccinesammensætning til anvendelse ifølge krav 11, hvor adjuvans-blandingen består af en acrylsyrepolymer og en blanding af en metaboliser- bar olie, der omfatter en eller flere terpencarbonhydrider og en polyoxyethy-len-polyoxypopylen-blokcopolymer, der er til stede i en endelig koncentration på ca. 1 -25% v/v.
16. Vaccinesammensætning til anvendelse ifølge krav 15, hvor acrylsyre-polymeren af adjuvansblandingen er en carbomer.
17. Vaccinesammensætning til anvendelse ifølge krav 15, hvor den metabo-liserbare olie i adjuvansblandingen er en terpencarbonhydrid udvalgt fra gruppen af squalan og squalen.
18. Vaccine sammensætning til anvendelse ifølge et hvilket som helst af kravene 11-17, yderligere omfattende co-administration af mindst et yderligere bakterin udvalgt fra gruppen bestående af Haemonphilus parasuis, Pasteu-rella multiocida, Streptococcum suis, Actinobacillus pleuropneumoniae, Bor-detella bronchiseptica, Salmonella choleraesuis, Erysipelothrix rhusiopathiae og leptospira-bakterier.
19. Vaccine sammensætning til immunisering af et dyr mod infektion med Mycoplasma hyopneumoniae og porcin circovirus (PCV), hvilken vaccinesammensætning omfatter en immuniserende mængde af Mycoplasma hyop-neumoniae-bakterin; en immuniserende mængde af porcin circovirus (PCV); og et adjuvanssystem omfattende en acrylsyrepolymer, en metaboliserbar olie og en polyoxyethylen-polyoxypropylen-blokcopolymer i form af en olie-i-vand-emulsion; hvilken vaccinesammensætning fremkalder beskyttende immunitet mod Mycoplasma hyopneumoniae efter en enkelt indgivelse.
DK07019279.4T 2002-05-17 2003-05-14 Kombineret vaccine mod mycoplasma hyopneumoniae og porcin circovirus DK1870109T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/150,597 US7018638B2 (en) 2000-12-19 2002-05-17 Mycoplasma hyopneumoniae bacterin vaccine
EP03813041.5A EP1506006B1 (en) 2002-05-17 2003-05-14 Improved combined vaccine against mycoplasma hyopneumoniae and porcine viruses

Publications (1)

Publication Number Publication Date
DK1870109T3 true DK1870109T3 (da) 2016-04-25

Family

ID=32680190

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07019279.4T DK1870109T3 (da) 2002-05-17 2003-05-14 Kombineret vaccine mod mycoplasma hyopneumoniae og porcin circovirus

Country Status (20)

Country Link
US (4) US7018638B2 (da)
EP (2) EP1506006B1 (da)
JP (2) JP2006515304A (da)
KR (1) KR101056622B1 (da)
CN (1) CN1305524C (da)
AR (1) AR039545A1 (da)
AU (1) AU2003303129B2 (da)
BR (1) BR0310082A (da)
CL (1) CL2010000397A1 (da)
DK (1) DK1870109T3 (da)
ES (2) ES2569063T3 (da)
HK (1) HK1111103A1 (da)
HR (1) HRP20041068B1 (da)
ME (1) ME00569B (da)
MX (1) MXPA04011218A (da)
NZ (1) NZ537014A (da)
RS (1) RS54390B1 (da)
TW (1) TWI320715B (da)
WO (1) WO2004058142A2 (da)
ZA (1) ZA200410153B (da)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39494E1 (en) * 1992-02-27 2007-02-27 Intervet Inc. Inactivated mycoplasma hyopneumoniae and uses therefor
DK0757556T3 (da) * 1994-04-11 2006-10-02 Wyeth Corp Borrelia Burgdorferi-bakterin
EP0839912A1 (en) * 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US20040224327A1 (en) * 1996-10-30 2004-11-11 Meulenberg Johanna Jacoba Maria Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
EP1157121B1 (en) * 1999-03-08 2013-04-24 Boehringer Ingelheim Vetmedica GmbH Prrsv replicon
AU4482200A (en) * 1999-04-22 2000-11-10 United States Department Of Agriculture Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142
MY128159A (en) * 2000-06-30 2007-01-31 Wyeth Corp Methods and composition for oral vaccination
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
TWI238721B (en) * 2003-06-20 2005-09-01 Animal Technology Inst Taiwan Swine enzootic vaccine, its producing method and usage
TW200604526A (en) * 2004-06-18 2006-02-01 Unviersity Of Minnesota Identifying virally infected and vaccinated organisms
US7632636B2 (en) * 2004-09-21 2009-12-15 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome isolates and methods of use
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US8834891B2 (en) * 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
US20060251827A1 (en) * 2005-05-09 2006-11-09 Applied Materials, Inc. Tandem uv chamber for curing dielectric materials
PT1904631E (pt) 2005-06-24 2012-07-16 Univ Minnesota Vírus srrp, clones infecciosos, os seus mutantes e processos de utilização
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
KR20080069232A (ko) * 2005-11-04 2008-07-25 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 스플리트 인플루엔자 백신에 대한 보조제로서 유리 수성상계면활성제를 갖는 에멀젼
ES2420829T3 (es) 2005-11-04 2013-08-27 Novartis Vaccines And Diagnostics S.R.L. Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
DK2371383T3 (da) * 2005-12-29 2015-11-30 Boehringer Ingelheim Vetmed Anvendelse af en PCV2-immunogen sammensætning til mindskning af kliniske symptomer i grise
HUE054868T2 (hu) * 2005-12-29 2021-10-28 Boehringer Ingelheim Animal Health Usa Inc Multivalens PVC2 immunogén készítmények és eljárások ezek elõállítására
BRPI0710550A2 (pt) * 2006-04-10 2011-08-16 Intervet Int Bv uso de uma dose imunogênica de material imunogênico de mycoplasma hyopneumoniae e uma dose imunogênica de vìrus de prrs atenuado vivo, kit de vacina, e, método para a vacinação de porcos
US20100129397A1 (en) * 2006-12-11 2010-05-27 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
RU2520087C2 (ru) * 2006-12-15 2014-06-20 Бёрингер Ингельхайм Ветмедика, Инк. Лечение свиней с помощью антигена pcv2
EP1941903A1 (en) * 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
CL2008001806A1 (es) * 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
MX2010005014A (es) * 2007-11-06 2010-06-30 Wyeth Llc Vacuna viva avirulenta de mycoplasma hyopneumoniae con adyuvante.
AU2012261741B2 (en) * 2007-11-06 2016-02-25 Zoetis Services Llc Mycoplasma hyopneumoniae avirulent-adjuvanted live vaccine
EP2231182A4 (en) * 2007-12-31 2012-08-22 Boehringer Ingelheim Vetmed PCV2-ORF2-VIRUSELY PARTICLES WITH FREMDAMINO-ACID INSERTION
US20090317423A1 (en) 2008-01-23 2009-12-24 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
WO2009103037A1 (en) * 2008-02-15 2009-08-20 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
CN101363865B (zh) * 2008-05-26 2013-03-06 北京庄笛浩禾生物医学科技有限公司 一种猪蓝耳病毒胶体金检测试纸条、其制备方法及其应用
EP2291194B1 (en) * 2008-06-25 2017-02-22 Braasch Biotech LLC Compositions and methods for enhanced somatostatin immunogenicity
US20100003278A1 (en) * 2008-07-03 2010-01-07 Boehringer Ingelheim Vetmedica, Inc. Immunological Compositions Effective for Lessening the Severity or Incidence of PRRSV Signs and Methods of Use Thereof
US20110117129A1 (en) * 2008-08-25 2011-05-19 Boehringer Ingelheim Vetmedica, Inc. Vaccine Against Highly Pathogenic Porcine Reproductive and Respiratory Syndrome (HP PRRS)
CN102307590A (zh) 2009-02-10 2012-01-04 诺华有限公司 具有减少量的角鲨烯的流感疫苗
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
BR112013004594B1 (pt) * 2010-08-27 2020-07-28 Intervet International B. V. método para a determinação de um conteúdo de antígeno
CN101954079B (zh) * 2010-09-21 2012-11-28 江苏省农业科学院 猪支原体肺炎活疫苗的疫苗佐剂及其制备方法和应用
DK2675475T3 (da) 2011-02-17 2015-09-14 Boehringer Ingelheim Vetmed Ny europæisk prrsv-stamme
MX346636B (es) 2011-02-17 2017-03-27 Boehringer Ingelheim Vetmedica Gmbh Procedimiento para la produccion a escala comercial de prrsv.
PL2691530T3 (pl) 2011-06-10 2019-02-28 Oregon Health & Science University Glikoproteiny i rekombinowane wektory CMV
WO2013017570A1 (en) 2011-07-29 2013-02-07 Boehringer Ingelheim Vetmedica Gmbh Novel prrs virus inducing type i interferon in susceptible cells
US9187731B2 (en) 2011-07-29 2015-11-17 Boehringer Ingelheim Vetmedica Gmbh PRRS virus inducing type I interferon in susceptible cells
CN103157100B (zh) * 2011-12-08 2014-09-24 普莱柯生物工程股份有限公司 副猪嗜血杆菌病、猪链球菌病二联灭活疫苗及其制备方法
US9474692B2 (en) * 2012-01-13 2016-10-25 Boehringer Ingelheim Vetmedica Gmbh Kit for the preparation of a vaccinating agent
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
CN104968365B (zh) 2012-12-28 2018-04-03 勃林格殷格翰动物保健有限公司 支原体疫苗的制备方法
EP2938356B1 (en) * 2012-12-28 2020-05-13 Boehringer Ingelheim Vetmedica GmbH Immunogenic composition comprising mycoplasma antigens
CN103908665B (zh) * 2013-01-05 2016-05-25 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
CN103071151B (zh) * 2013-01-17 2014-07-23 江苏省农业科学院 猪支原体肺炎疫苗专用稀释剂及其制备方法
CN103961695B (zh) * 2013-02-06 2016-09-07 普莱柯生物工程股份有限公司 一种预防和治疗猪呼吸道综合征的疫苗组合物及其制备方法和应用
CN105073130A (zh) 2013-03-15 2015-11-18 勃林格殷格翰动物保健公司 猪生殖与呼吸综合征病毒、组合物、疫苗及使用方法
CN104096222B (zh) * 2013-04-08 2016-09-14 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
EP2994162B1 (en) 2013-05-08 2021-04-07 Pharmgate Biologics Inc. Vaccine for pcv2 and mycoplasma
WO2015048115A1 (en) 2013-09-25 2015-04-02 Zoetis Llc Pcv2b divergent vaccine composition and methods of use
EA035265B1 (ru) 2013-10-02 2020-05-21 Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. Вариант белка opc2 pcv2 и содержащие его вирусоподобные частицы
CN104248759B (zh) * 2013-11-19 2017-05-10 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
CN104857508B (zh) * 2014-02-21 2018-03-16 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
US10064930B2 (en) * 2015-01-16 2018-09-04 Boehringer-Ingelheim Vermedica, Inc. Immunogenic compositions and methods for pigeon fever
RU2744172C2 (ru) * 2015-11-13 2021-03-03 Эпплайд Лайфсайенсиз Энд Системс, Ллс Система и способ определения состояния здоровья и пола цыпленка
CN112618710B (zh) * 2019-09-24 2023-09-29 华南理工大学 一种植物糖原猪口服接种疫苗纳米佐剂及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3790665A (en) 1968-02-23 1974-02-05 Haver Lockhart Labor Inc Injectable adjuvant,method of preparing same and compositions including such adjuvant
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPH0832637B2 (ja) 1985-02-14 1996-03-29 アクゾ・エヌ・ヴエー 合成免疫原
EP0283085B1 (en) 1987-03-17 1992-11-11 Akzo N.V. Adjuvant mixture
ES2052674T3 (es) 1987-11-03 1994-07-16 Syntex Inc Adyuvante de vacunas.
ZA906806B (en) * 1989-08-31 1991-06-26 Ici Australia Operations Plants
EP0597852B2 (en) * 1990-05-29 2005-08-10 Wyeth Holdings Corporation Swine pneumonia vaccine and method for the preparation thereof
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
DE69535520T2 (de) * 1994-05-10 2008-02-07 Wyeth Abgeänderter, verbesserter BRSV Lebend- Impfstoff
UA78180C2 (uk) * 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6632439B2 (en) * 1999-09-29 2003-10-14 Novartis Animal Health, Inc. Fusobacterium necrophorum vaccine and method for making such vaccine
US6585981B1 (en) * 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine

Also Published As

Publication number Publication date
US7018638B2 (en) 2006-03-28
HRP20041068B1 (hr) 2018-10-05
EP1506006A2 (en) 2005-02-16
ES2569063T3 (es) 2016-05-06
KR20050007402A (ko) 2005-01-17
WO2004058142A2 (en) 2004-07-15
AU2003303129B2 (en) 2009-10-08
US7622124B2 (en) 2009-11-24
EP1506006B1 (en) 2013-07-31
JP5700861B2 (ja) 2015-04-15
RS54390B1 (sr) 2016-04-28
KR101056622B1 (ko) 2011-08-16
US20100062018A1 (en) 2010-03-11
CN1305524C (zh) 2007-03-21
WO2004058142A3 (en) 2004-11-04
EP1870109A1 (en) 2007-12-26
NZ537014A (en) 2009-09-25
CN1652817A (zh) 2005-08-10
MXPA04011218A (es) 2005-02-14
TW200306854A (en) 2003-12-01
EP1870109B1 (en) 2016-03-16
ES2431988T3 (es) 2013-11-29
ZA200410153B (en) 2014-07-30
AU2003303129A1 (en) 2004-07-22
HRP20041068A2 (en) 2004-12-31
HK1111103A1 (zh) 2008-08-01
AR039545A1 (es) 2005-02-23
US20030017171A1 (en) 2003-01-23
US7169394B2 (en) 2007-01-30
JP2006515304A (ja) 2006-05-25
JP2013189438A (ja) 2013-09-26
ME00569A (en) 2011-12-20
ME00569B (me) 2011-12-20
BR0310082A (pt) 2007-04-10
CL2010000397A1 (es) 2010-10-15
US20060228373A1 (en) 2006-10-12
US20070134269A1 (en) 2007-06-14
US7959927B2 (en) 2011-06-14
RS99704A (en) 2006-12-15
TWI320715B (en) 2010-02-21

Similar Documents

Publication Publication Date Title
DK1870109T3 (da) Kombineret vaccine mod mycoplasma hyopneumoniae og porcin circovirus
US7666439B2 (en) Mycoplasma hyopneumoniae bacterin vaccine